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To identify genetic variants associated with breast cancer prognosis we conduct a meta-
analysis of overall survival (OS) and disease-free survival (DFS) in 6042 patients from four
cohorts. In young women, breast cancer is characterized by a higher incidence of adverse
pathological features, unique gene expression proﬁles and worse survival, which may relate
to germline variation. To explore this hypothesis, we also perform survival analysis in 2315
patients aged ≤ 40 years at diagnosis. Here, we identify two SNPs associated with early-
onset DFS, rs715212 (Pmeta= 3.54 × 10−5) and rs10963755 (Pmeta= 3.91 × 10−4) in
ADAMTSL1. The effect of these SNPs is independent of classical prognostic factors and there
is no heterogeneity between cohorts. Most importantly, the association with rs715212 is
noteworthy (FPRP <0.2) and approaches genome-wide signiﬁcance in multivariable analysis
(Pmultivariable= 5.37 × 10−8). Expression quantitative trait analysis provides tentative evidence
that rs715212 may inﬂuence AREG expression (PeQTL= 0.035), although further functional
studies are needed to conﬁrm this association and determine a mechanism.
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Breast cancer is the second leading cause of cancer-relateddeath in women with nearly 450,000 deaths per yearworldwide, despite advances in effective chemotherapy1.
Modern chemotherapy regimens include anthracyclines and
increasingly taxanes, before and/or after surgery (http://www.
cancerresearchuk.org/). Patients are stratiﬁed according to clinical
and pathological characteristics of the cancer to predict prognosis,
select treatment regimen and to determine appropriate surgical
options for individual patients. Frequently, these decisions are
made on the basis of prognostic tools and guidelines which
consider tumour characteristics (size, grade and hormone
receptors), nodal involvement, onset age, family history and the
mutation status of high-risk genes such as BRCA1 and BRCA22.
These prognostic tools help to balance the beneﬁts of therapy
against their side effects. However, patients with the same tumour
characteristics and treatment frequently have different outcomes
which suggests that additional factors such as inherited variation
may account for these differences.
Many studies have demonstrated that germline variants con-
tribute to the aetiology of breast cancer. They include several
genome-wide association studies (GWASs) which have identiﬁed
nearly 100 common low-penetrance breast cancer-associated
alleles (odds ratios: 1.05–1.57)3. These low-penetrance alleles
account for ~14% of the familial risk of disease while high-
penetrance mutations in genes such as BRCA1 and BRCA2 and
moderate-penetrance alleles in genes such as PALB2, ATM and
CHEK2 account for a further ~16% of familial risk4.
Familial studies were among the ﬁrst to indicate that inherited
variants also inﬂuence breast cancer prognosis5 and many
germline variants associated with survival have been identiﬁed.
For example, germline mutations in CHEK26 and PALB27 have
been implicated in poor prognosis and single-nucleotide poly-
morphisms (SNPs) have been associated with the risk of devel-
oping either oestrogen receptor (ER)-positive8 or -negative9
breast cancer subtypes, which have differing outcomes. More
recently, many studies including GWASs have identiﬁed SNPs
Table 1 Clinical characteristics of patient cohorts
ABCFS HEBCS POSH stage 1 SUCCESS-A POSH stage 2 P-value
SNPs passing QC
Observed 508,505 501,882 503,568 566,645 116
Imputed 5,150,529 5,395,529 5,196,034 5,006,474 0
No. of cases passing QC 202 798 556 3183 1303
Age at diagnosis median
(range)
— 53 (22–87) 36 (18–40) 54 (19–85) 37 (20–40) < 2.2 × 10−16
No. of cases aged ≤ 40 at
diagnosis
202 119 (15%) 556 (100%) 337 (11%) 1303 (100%)
Deceased (all cause) 67 (33%) 317 (40%) 268 (48%) 171 (5%) 278 (21%)
Deceased and aged ≤ 40a 67 (33%) 45 (38%) 268 (48%) 13 (4%) 278 (21%)
OS median (IQR), years 15.8 (14.2) 8.0 (5.2) 4.8 (4.5) 4.8 (2.4) 6.8 (3.2) < 2.2 × 10−16
Disease progression — 368 (46%) 288 (52%) 335 (11%) 325 (25%)
Progressed and aged ≤ 40a — 65 (55%) 288 (52%) 38 (11%) 325 (25%)
DFS median (IQR), years — 5.0 (2.7) 3.1 (5.5) 4.8 (2.7) 6.3 (3.7) < 2.2 × 10−16
Oestrogen receptor (ER)
Positive 91 (45%) 515 (65%) 193 (35%) 2189 (69%) 1014 (78%)
Negative 75 (37%) 225 (28%) 362 (65%) 975 (31%) 283 (22%) 1.00 × 10−13
Missing 36 (18%) 58 (7%) 1 (<1%) 19 (1%) 6 (< 1%)
Progesterone receptor (PR)
Positive — — 112 (20%) 2018 (63%) 713 (55%)
Negative — — 369 (66%) 1143 (36%) 328 (25%) 1.00 × 10−13
Missing 202 (100%) 798 (100%) 75 (14%) 22 (1%) 262 (20%)
HER2
Positive — 86 (11%) 105 (19%) 952 (30%) 347 (27%)
Negative — 400 (50%) 407 (73%) 2166 (68%) 776 (59%) 1.49 × 10−11
Missing 202 (100%) 312 (39%) 44 (8%) 65 (2%) 180 (14%)
Triple negative (ER, PR, HER2) — — 283 (51%) 518 (16%) 104 (8%) 1.00 × 10−13
Grade
1 — 140 (18%) 13 (2%) 144 (5%) 97 (7%)
2 — 306 (38%) 90 (16%) 1523 (48%) 508 (39%)
3 — 275 (34%) 435 (78%) 1494 (47%) 670 (51%) 1.00 × 10−13
Missing 202 (100%) 77 (10%) 18 (3%) 22 (1%) 28 (2%)
Tumour size
Size (mm) average (range) — 25.2 (1–100) 29.7 (0–160) 25.1 (1–220) 25.7 (0.5–170) 0.038
T stage
1 — 381 (48%) 227 (41%) 1302 (41%) 654 (50%)
2 — 297 (37%) 228 (41%) 1645 (52%) 505 (39%)
3 — 50 (6%) 45 (8%) 172 (5%) 80 (6%)
4 — 47 (6%) 4 (1%) 43 (1%) 1 (< 1%) 1.00 × 10−13
Missing 202 (100%) 23 (3%) 52 (9%) 21 (1%) 63 (5%)
Nodal metastasis
Positive — 441 (55%) 271 (49%) 2044 (64%) 679 (52%)
Negative — 326 (41%) 258 (46%) 1115 (35%) 613 (47%) 1.00 × 10−13
Missing 202 (100%) 31 (4%) 27 (5%) 24 (1%) 11 (1%)
aPercentages using number of cases aged ≤ 40 years at diagnosis as the denominator
P-value for comparison between all cohorts with data (n= 3 to 5), Pearson’s Χ2 tests were used for categorical variables and Kruskal–Wallis rank sum tests were used to compare continuous traits
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directly associated with breast cancer survival that are largely
independent of traditional tumour prognostic factors10. Most of
these loci have small effect sizes (hazard ratio (HR) < 1.5) and it
is important to note that many loci reported by GWASs do not
reach genome-wide signiﬁcance which suggests that some of the
previous GWASs were underpowered due to small sample size.
Indeed, it has been suggested that extremely large sample sizes are
needed to establish genome-wide levels of signiﬁcance in breast
cancer survival studies10. Alternatively, focussing on a smaller
cohort of patients with a particular breast cancer subtype may
increase power by reducing genetic heterogeneity. These genetic
determinants of prognosis are important because they could
improve prognostic models, aid selection of appropriate treat-
ments, and suggest targets for new therapies. For example,
tumour gene expression proﬁles perform equally well or better
than clinicopathologic models, possibly because they reﬂect a
larger component of germline determinants of gene expression in
an established tumour than models based on clinicopathologic
features11.
The principal aim of this study is to identify genetic determi-
nants of breast cancer prognosis using a meta-analysis of four
GWASs and a ﬁfth replication cohort. We also investigate the role
of common germline variation in a subset of patients with early
onset (aged ≤ 40 years at diagnosis). Although breast cancer is
uncommon in young women, with only 7% of patients aged ≤ 40
years at diagnosis and 1% < 30 years12, it represents the most
frequent form of non-skin cancer in young women, accounting
for ~40% of cases13. Furthermore, women diagnosed between the
ages of 15 and 39 years have a lower 5-year survival rate (83.5%)
than women aged 40 to 49 years (89.1%) (www.cancerresearchuk.
org). The worse survival of early-onset cases has been attributed
to a higher incidence of adverse pathological features (higher
histological grade14, more frequent ER- and progesterone recep-
tor (PR)-negative tumours)15,16 but multivariable analysis has
demonstrated that age is an independent risk factor after
adjusting for stage, treatment and tumour characteristics12.
Analyses of gene expression proﬁles have shown that tumours
arising in young women can be distinguished by 367 biologically
relevant gene sets16 and that ER-positive tumours in pre-
menopausal women overexpress AREG, TFPI2, AMPH, DBX2,
RP5–1054A22.3 and KLK5, and underexpress ESR1, CYP4Z1,
RANBP3L, FOXD2 and PEX317,18. The impact of epidemiological
risk factors, such as obesity, also differs between premenopausal
women, where it reduces the risk of ER-positive tumours, and
postmenopausal women where it increases overall suscept-
ibility19,20. These observations have led to the suggestion that,
from an aetiological perspective, early-onset breast cancer may
represent a different type of disease with a unique underlying
biology and response to epidemiological risk factors that could be
inﬂuenced by germline variation.
We identify three association signals with suggestive sig-
niﬁcance levels and without heterogeneity between cohorts (1:
rs715212 and rs10963755; 2: rs12302097; and 3: rs410155). The
most signiﬁcant of these is rs715212, situated in intron 19 of
ADAMTSL1, which increases the risk of disease progression but
only in patients with early onset (aged ≤ 40 years at diagnosis).
When adjusting for the known prognostic factors, this association
approaches a genome-wide level of signiﬁcance and is assessed as
noteworthy by the false positive report probability (FPRP < 0.2).
We also demonstrate that rs715212 is nominally associated with
the expression of AREG. We therefore conclude that the asso-
ciation between ADAMTSL1 and breast cancer prognosis may
involve an interaction with AREG expression, although further
functional studies are needed to conﬁrm this association and to
determine the mechanism.
Results
Comparison of clinicopathologic features between cohorts.
Stage-1 breast cancer samples came from four cohorts from
Australia (Australian Breast Cancer Family Study (ABCFS)),
Helsinki (Helsinki breast cancer study (HEBCS)), the United
Kingdom (Prospective Study of Outcomes in Sporadic vs. Her-
editary breast cancer (POSH)) and Germany (SUCCESS-A). A
further 1303 independent patients from the POSH cohort were
used for replication analysis at stage-2 (Table 1, see Methods for a
full description of these cohorts). The baseline characteristics
among the stage-1 and validation cohorts were signiﬁcantly dif-
ferent (Table 1). These differences are largely due to the POSH
cohort, which only recruited patients with early onset (age ≤ 40
years at diagnosis), and the selection of patients with triple-
negative breast cancer (TNBC) or survival extremes from the
POSH cohort at stage-1. As a result, the stage-1 POSH cohort had
the highest frequency of ER, PR and HER2 negativity, grade 3
tumours, larger average tumour size and the shortest median time
to disease progression and mortality. Despite these differences,
the ABCFS, HEBCS and POSH stage-1 cohorts were similar in
terms of the incidence of disease progression and mortality. In
comparison, SUCCESS-A and POSH stage-2 had lower inci-
dences of progression and mortality. To address these differences,
survival analyses at stages 1 and 2 were adjusted for ER status
and, for replicating SNPs, multivariable models were constructed
using pooled data from stages 1 and 2.
Stage-1 survival analysis and meta-analysis. Following standard
quality control (QC, see Methods), 4739 patients from four
cohorts ABCFS (N= 202), HEBCS (N= 798), POSH (N= 556)
and SUCCESS-A (N= 3183) and 5,848,861 SNPs (813,964
observed and 5,034,897 imputed) were used for genome-wide
analysis of overall survival (OS) at stage-1 (Table 1 and Supple-
mentary Table 1). The ABCFS cohort was excluded from the
early-onset and disease-free survival (DFS) analyses because data
on progression were unavailable. Consequently, 4537 patients
were used for DFS in all cases and 1102 patients for early-onset
analyses at stage-1. Among the survival analyses performed at
stage-1 there were 823 events for OS, 991 events for DFS (all
cases), 326 events for early-onset OS and 391 events for early-
onset DFS. According to these sample sizes and event rates, we
estimated that the combined stage-1 analysis of OS and DFS had
80% power to detect common SNPs (minor allele frequency
(MAF)=0.3) with modest effects (HR=1.4, Pα= 5 × 10−8). Due to
its smaller sample size, the analysis of OS and DFS in early-onset
cases was estimated to have 80% power to detect SNPs with
slightly larger effect sizes (OS: HR=1.7, DFS: HR=1.6, Supple-
mentary Fig. 2).
For each cohort, the quantile–quantile (QQ) plots and low
genomic inﬂation factors (λ≤ 1.05) for OS and DFS in all cases
and in the early-onset subset demonstrate good agreement
between observed and expected P-values until the tail of the
distributions where SNPs with P-values <10−4 deviated from the
null distribution (Supplementary Figs. 3–5). Systematic biases
such as population stratiﬁcation are therefore unlikely to
contribute to the signiﬁcance of these SNPs. Comparison of the
QQ plots for OS and DFS showed that analyses of DFS tended to
identify more SNPs with low P-values (PCox regression≤ 10−4)
which is consistent with the larger number of events.
Following Cox regression, we used a ﬁxed effects meta-analysis
to combine evidence across the stage-1 cohorts and visualized
these results in a Manhattan plot by selecting the most signiﬁcant
P-value for each SNP from the analysis of OS or DFS, in all cases
and the early-onset subset (Fig. 1). Despite meta-analysis of upto
4739 patients and sufﬁcient power to detect common SNPs
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(MAF=0.3) with modest effect sizes (HR=1.4 for all patients and
HR=1.6 for early onset), no associations achieved genome-wide
signiﬁcance at stage-1. We therefore used our selection criteria
(see Methods) to select 87 SNPs for assessment at stage-2, with P-
values from the stage-1 meta-analysis ranging from 3.5 × 10−7 to
0.008 (Supplementary Data 1).
To select additional SNPs, we conducted a literature search,
which identiﬁed 73 variants associated with breast cancer
survival, excluding studies that used any of our stage-1 cohorts.
In our stage-1 meta-analyses, 57 of the published SNPs were
genotyped and tested and 12 of them were replicated (Pmeta≤
0.05, Supplementary Data 2). From the 12 published SNPs with
replication, 3 were selected for stage-2 analysis although 2 of
these, which were the most signiﬁcant, had already been chosen
by our selection criteria. In total, 9 replicating SNPs were
discounted either because nearby variants with higher signiﬁ-
cance had been selected (n=3), other variants in the gene had
previously been tested (n=2) or because the signiﬁcance level was
modest (Pmeta≥ 0.01, n=4). An additional 7 SNPs were selected
for their association with onset age and or for their potential
applications for risk prediction despite nonsigniﬁcance at stage-1,
making a total of 95 SNPs for genotyping at stage-2 (Supple-
mentary Data 1).
Replication and meta-analysis of stages 1 and 2. For replication
at stage-2, 83 of the 95 selected SNPs were successfully genotyped
by LGC Genomics using KASP chemistry in 1303 patients from
the POSH cohort. QC excluded two SNPs with signiﬁcant
deviation from Hardy–Weinberg equilibrium (PHardy–Weinberg≤
1 × 10−10) and ﬁve monomorphic SNPs leaving 76 SNPs for
analysis (Supplementary Data 1). After testing for association
with OS and DFS, we identiﬁed three independent signals that
were represented by four SNPs (1: rs715212 and rs10963755; 2:
rs12302097; and 3: rs410155) with replication P-values from Cox
regression ranging from 0.009 to 0.043 and effects in the same
direction as the complimentary stage-1 analysis (Supplementary
Data 1). For these SNPs, we used a ﬁxed effects meta-analysis to
determine their ﬁnal effect size and signiﬁcance by combining
evidence from stages 1 and 2. Although none of the four SNPs
reached a genome-wide level of signiﬁcance, they were highly
signiﬁcant (Pmeta ranging from 3.54 × 10−5 to 1.28 × 10−4) and
there was no evidence of heterogeneity between cohorts despite
the reported differences in clinicopathologic features (Table 2).
Furthermore, the association with rs715212 was determined to be
noteworthy by the FPRP ≤ 0.2.
The effect size and signiﬁcance of the replicating SNPs after
meta-analysis of stages 1 and 2 and in each individual cohort
(ABCFS, HEBCS, POSH stages 1 and 2 and SUCCESS-A) are
shown in a forest plot (Fig. 2). The forest plot presents the most
signiﬁcant end point from the meta-analysis of stages 1 and 2 for
all SNPs except rs12302097. For rs12302097, the association with
DFS in all cases is presented rather than DFS in the early-onset
subset, which is slightly more signiﬁcant. This is because
rs12302097 had similar effects in patients with early and late
onset, indicating that this SNP inﬂuences prognosis in all
patients.
rs715212 (Pmeta= 3.54 × 10−5, HR=1.27) and rs10963755
(Pmeta= 3.91 × 10−4, HR=1.22) were associated with an increased
risk of disease progression, but interestingly this association was
restricted to patients with early onset (Table 2). For both of these
SNPs, the association with DFS was apparent in all four cohorts
of early-onset patients (HEBCS, POSH1, SUCCESS-A and
POSH2) and there was no evidence for association in patients
with later onset (Fig. 2 and Table 2). The risk alleles for rs715212
(Pallelic association= 1.03 × 10−5, OR=1.36) and rs10963755 (Pallelic
association= 1.98 × 10−4, OR=1.29) were signiﬁcantly more com-
mon in early-onset patients with disease progression and there
was no difference between patients with and without progression
who were aged over 40 years old at diagnosis (Supplementary
Table 2).
Although rs715212 and rs10963755 are only separated by
4.7 kb, the linkage disequilibrium between them is weak (r2=
0.33) and they were consequently treated as independent loci
when selecting SNPs for replication. However, a multivariable
analysis of DFS using pooled data in early-onset patients from
HEBCS, POSH and SUCCESS-A showed that these SNPs
represent a single association signal since rs10963755 did not
retain signiﬁcance (Ppooled= 0.402) after adjusting for rs715212
(Ppooled= 0.003).
rs12302097 is associated with an increased risk of relapse in all
patients (Pmeta= 7.54 × 10−5, HR=1.30) with a similar effect in
patients with early (Pmeta= 6.77 × 10−5, HR=1.45) and late onset
(Pmeta= 0.0742, HR=1.19, Table 2). Finally, rs410155 is asso-
ciated with an increased risk of mortality in all cases (Pmeta=
1.28 × 10−4, HR=1.34), with similar effect in patients with early
(Pmeta= 0.0049, HR=1.32) and late onset (Pmeta= 0.0066,
HR=1.32). Results from all survival and meta-analyses for the
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Fig. 1 Genome-wide analysis of breast cancer survival. The Manhattan plot shows the result of the stage-1 meta-analysis. Results are plotted as –log10 of
the P-value from Cox regression. For each SNP the most signiﬁcant P-value is selected from the analysis of either overall survival (OS) or disease-free
survival (DFS) in all patients or the subset with early onset. The four most signiﬁcant SNPs after meta-analysis of stages 1 and 2 are highlighted in green
(rs410155 and rs12302097 associated with OS and DFS respectively in the whole cohort and rs715212 and rs10963755 associated with DFS in patients
with early onset). This plot was produced using the qqman R package
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95 SNPs that were selected for genotyping at stage-2 are given in
Supplementary Data 1.
Univariate Kaplan–Meier (KM) plots for the replicating SNPs
and most signiﬁcant outcomes were produced using pooled data
from stages 1 and 2 (Fig. 3). Excluding rs410155, the signiﬁcance
levels and effect sizes from the pooled analyses were very similar
to those obtained from meta-analysis (rs715212 Ppooled= 1.94 ×
10−5, HR=1.28; rs10963755 Ppooled= 6.48 × 10−4, HR=1.21;
rs12302097 Ppooled= 1.65 × 10−4, HR=1.28, Table 3). For
rs410155, the pooled analysis was less signiﬁcant and the HR
was slightly smaller (Ppooled= 0.015, HR=1.20). The KM plots for
rs715212 and rs12302097 were consistent with the additive model
tested while the plots for rs10963755 and rs410155 were
indicative of a dominant effect. For rs10963755 and rs410155,
the dominant model was equally signiﬁcant and the effect sizes
were slightly larger (rs10963755 Pdominant= 6.46 × 10−4,
HR=1.30; rs410155 Pdominant= 0.0120, HR=1.23).
Multivariable models. We used multivariable Cox regression in
pooled data from stages 1 and 2 to determine whether the
replicating SNPs were independent of the known prognostic
factors that were available across all studies except ABCFS. After
adjustment for ER status, tumour grade, maximum tumour dia-
meter, axillary nodal status and study, the association between
rs715212 and risk of disease progression in patients with early
onset approached a genome-wide level of signiﬁcance (Pmultivariable
= 5.37 × 10−8, HR=1.38, Table 3). The associations between
rs10963755 and DFS in patients with early onset (Pmultivariable=
4.51 × 10−5, HR=1.27) and between rs410155 and OS in all cases
(Pmultivariable= 0.0023, HR=1.28), also became stronger after
adjustment for tumour characteristics and study compared with
univariate analysis. For rs12302097, the association with DFS in all
cases (Pmultivariable= 0.001, HR=1.26) was less signiﬁcant after
adjustment.
Functional inference. To explore the functional relevance of the
regions associated with survival, we used HaploReg v4.121, Reg-
ulomeDB22 and SeattleSeq23 to determine if the risk SNPs and
their proxies (r2≥ 0.2) are located within putative functional
elements such as active histone marks or transcription factor (TF)
binding motifs (Supplementary Data 3). rs715212 and
rs10963755 are located in intron 19 of the ADAMTSL1 gene and
both are reported to alter TF binding motifs (Fig. 4a and Sup-
plementary Data 3). The chromatin surrounding rs715212 is
characterized as an enhancer in breast myoepithelial primary cells
(strongly enriched for TF binding sites, moderately enriched for
DNase peaks and conserved elements), while rs10963755 maps to
a quiescent region. rs12302097 is located in a 64 kb region of
linkage disequilibrium (LD) (r2> 0.2) between carbohydrate sul-
fotransferase 11 (CHST11, 38 kb upstream) and thioredoxin
reductase 1 (TXNRD1, 68.5 kb downstream). The chromatin in
this region has properties of weak transcription in variant human
mammary epithelial cells (vHMECs) and the SNP has been
shown to alter several TF binding motifs (Fig. 4b and Supple-
mentary Data 3). Finally, rs410155 is located between two
metallothionein genes: MT3 (8.7 kb upstream) and MT4 (11.6 kb
downstream, Fig. 4c). Although the surrounding chromatin in
breast myoepithelial primary cells is quiescent, this SNP has also
been predicted to alter TF binding motifs.
To gain further insight into the functional basis of each risk
SNP and its linked SNPs (r2≥ 0.2), we used the Genotype-Tissue
Expression (GTEx)24 portal to perform expression quantitative
trait locus (eQTL) analysis of the genes at either side of the index
SNP in breast mammary tissue. Although none of the index SNPs
were associated with the expression of their ﬂanking genes, SNPs
in weak LD with rs12302097 were found to be nominally
associated with the expression of CHST11 (rs56372209, PFastQTL
= 0.041, r2= 0.3) and TXNRD1 (rs73183724, PFastQTL = 0.031, r2
= 0.25, Supplementary Data 3). Using GTEx we also found that
several SNPs in complete LD with rs410155 including rs381706
were associated with the expression of MT1E (PFastQTL= 0.044)
and MT1F (PFastQTL= 0.026) in breast mammary tissue (Supple-
mentary Data 3). In whole blood, rs410155 is associated with the
expression of MT1E (P= 2.04 × 10−4) and MT1F (P= 2.22 ×
10−6) and rs12302097 is associated with TXNRD1 expression (P
= 0.001)25.
Several genes related to ADAMTSL1 have been implicated in
the development of normal breast tissue and in the initiation and
progression of breast cancer including ADAMTS126, ADAM1027,
ADAM1228 and ADAM1729. Of these, ADAM17, which plays a
key role in normal breast development via its cleavage and release
of amphiregulin (AREG) from the surface of breast epithelial
cells, appeared to be particularly relevant because two indepen-
dent studies have shown that AREG is overexpressed in ER-
positive breast tumours from premenopausal women vs. post-
menopausal women17,18. We therefore used GTEx to perform
further eQTL analysis, and found that rs715212 is nominally
associated with the expression of AREG (PFastQTL = 0.035) in
breast mammary tissue (Supplementary Fig. 6).
Triple-negative breast cancer. TNBC is an aggressive breast
cancer subtype with limited treatment options due to the lack of
Table 2 Summary of the most signiﬁcant SNPs from meta-analysis of stages 1 and 2 and their relationship with age of onset
End
point
SNPa Allelesb MAFc Flanking
genes
(distance to
SNP)
All patients Age of onset FPRPd
≤ 40 > 40
Pmeta HR (CI) Q Pmeta HR (CI) Q Pmeta HR (CI) Q
DFS rs715212 C/A 0.270 ADAMTSL1 0.0041 1.13
(1.04–1.23)
0.214 3.54 ×
10−5
1.27
(1.13–1.42)
0.773 0.7757 0.98
(0.87–1.11)
0.960 0.188
DFS rs10963755 C/G 0.245 ADAMTSL1 0.0147 1.11
(1.02–1.21)
0.108 3.91 ×
10−4
1.22
(1.09–1.37)
0.818 0.6834 0.97
(0.86–1.11)
0.103 0.837
DFS rs12302097 G/A 0.061 TXNRD1
(68.5 kb)
CHST1 (38 kb)
7.54 ×
10−5
1.30
(1.14–1.49)
0.594 6.77 ×
10−5
1.45
(1.21–1.74)
0.145 0.0742 1.19
(0.98–1.44)
0.992 0.665
OS rs410155 C/T 0.062 MT3 (8.7 kb)
MT4 (11.6 kb)
1.28 ×
10−4
1.34
(1.15–1.55)
0.994 0.0049 1.32
(1.09–1.60)
0.993 0.0066 1.32
(1.08–1.62)
0.346 0.599
aThe rs identiﬁer from dbSNP
bMinor/major alleles
cMinor allele frequency (MAF) from 1000 genomes
dFalse positive report probability (FPRP)
Pmeta, P-values from ﬁxed effects meta-analysis; HR, hazard ratio; CI 95% conﬁdence interval; Q, Cochran P-values for heterogeneity test
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expression of ER, PR and HER2 receptors. Studies have shown
that the immunoreactivity of MT3, which ﬂanks rs410155, is
associated with poor prognosis in TNBC patients30,31. To explore
the relationship with TNBC, the survival analyses were repeated
in a pooled subset of TNBC patients. rs410155 was the only SNP
that had a stronger association with prognosis in patients with
TNBC (Ppooled= 0.004 for OS in TNBC vs. Ppooled= 0.014 for OS
in all cases, Supplementary Table 3 and Supplementary Fig. 7).
Discussion
A recent study highlighted the difﬁculties of detecting variants
linked to breast cancer survival that were predicted to have small
effect sizes10. They suggested that very large sample sizes will be
required to detect common variants conferring HRs that may be
as low as 1.1, which is in line with ﬁndings from GWASs of breast
cancer risk. To our knowledge, only two loci, rs445820432 and
rs205961433, have conﬁdently been associated with breast cancer
survival at genome-wide levels of signiﬁcance despite the analysis
of up to 37,954 patients and an event rate of 7.6% (n= 2900
deaths). Our hypothesis was that enrichment for well-
characterized early-onset cases with worse prognosis might
facilitate detection by increasing the event rate, reducing genetic
heterogeneity and because variants with larger effect sizes might
underlie more aggressive forms of disease. Although the present
study has a comparatively small sample size (n= 6042 patients
including 2315 aged ≤ 40 years at diagnosis), the event rate is
signiﬁcantly higher over all patients (OS 18.2%, DFS 22.5%) and
the early-onset subset (OS 26.1%, DFS 30.9%) which is one of the
main determinants of power. Consequently, the combined ana-
lysis of stages 1 and 2 for DFS is estimated to have 80% power to
detect common SNPs (MAF=0.3) with an effect size of HR=1.31
in all patients and HR=1.42 in the early-onset subset at a
genome-wide level of signiﬁcance.
Despite sufﬁcient statistical power to detect common SNPs
with modest effect sizes no variants were identiﬁed at a genome-
wide level of signiﬁcance. This may reﬂect the confounding
impacts of a large number of factors that inﬂuence survival times,
including phenotypic heterogeneity, tumour biology and treat-
ment. However, three signals had suggestive levels of signiﬁcance
(1: rs715212 and rs10963755; 2: rs12302097; and 3: rs410155)
without heterogeneity between cohorts including one that was
estimated to be noteworthy according to the FPRP (rs715212
FPRP< 0.2). With the exception of rs12302097, the effect size
(HR) and signiﬁcance of these associations became stronger after
Cohort Events/patients HR (95% CI) P-value 
Hazard ratio (95% confidence interval) 
rs715212 early-onset DFS
rs12302097 DFS
rs410155 OS
rs10963755 early-onset DFS
Subtotal (I2 = 0.0%, P = 0.773)
Subtotal (I2= 0.0%, P = 0.818)
Subtotal (I2 = 0.0%, P = 0.594)
Subtotal (I2 = 0.0%, P = 0.994)
SUCCESS-A
POSH
POSH (Stage 2)
HEBCS
272/1280
169/3160
250/524
293/710
59/151
POSH (Stage 2) 320/1282
SUCCESS-A 333/3154
POSH 287/555
HEBCS 354/740
HEBCS 53/107
POSH 278/546
SUCCESS-A 38/332
POSH (Stage 2) 317/1281
POSH (Stage 2) 317/1275
SUCCESS-A 38/336
POSH 287/555
HEBCS 53/107
1.00 (0.67, 1.51) 0.9809
1.22 (1.09, 1.37) 3.91×10–4
1.21 (1.03, 1.42) 0.0198
1.51 (0.94, 2.42) 0.0875
1.22 (1.02, 1.46) 0.0266
1.12 (0.72, 1.75) 0.6233
1.16 (0.80, 1.70) 0.4333
1.32 (1.01, 1.72) 0.0430
1.42 (1.02, 1.97) 0.0372
1.30 (0.95, 1.78) 0.0985
1.36 (0.98, 1.87) 0.0635
1.23 (0.58, 2.59) 0.5937
1.34 (1.15, 1.55) 1.28×10–4
0.5 1 3 4 52
1.30 (1.14, 1.49) 7.54×10–5
1.40 (1.08, 1.81) 0.0108
1.11(0.84, 1.46) 0.4728
1.41(1.02, 1.96) 0.0380
1.33 (1.06, 1.65) 0.0124
2.14 (1.11, 4.11) 0.0224
1.27 (1.13, 1.42) 3.54×10–5
1.24 (1.05, 1.47) 0.0098
1.58 (1.00, 2.50) 0.0518
1.24 (1.04, 1.47) 0.0174
1.37 (0.90, 2.09) 0.1469
63/163ABCFS*
62/161ABCFS*
63/163ABCFS*
ABCFS
Fig. 2 Forest plot and meta-analysis for the four most signiﬁcant SNPs associated with overall survival (OS) or disease-free survival (DFS). Forest plot
showing the event rate, hazard ratio (HR), 95% conﬁdence interval (CI) and signiﬁcance level (P-value) from Cox regression in each cohort and the
combined analysis for the most signiﬁcant SNPs associated with DFS and OS. ABCFS*: evidence for association with OS in the ABCFS cohort is shown for
each SNP but these results are excluded from the meta-analyses of DFS. The SNP subtotal rows show the result for a ﬁxed effects meta-analysis across
four studies for rs715212, rs10963755 and rs12302097 and ﬁve studies for rs410155 using I2 and Cochran Q-statistic to assess heterogeneity in effect sizes
between cohorts
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adjustment for tumour characteristics in multivariable models.
This suggests that tumour characteristics are confounding factors
and that accounting for them in a multivariable model will
increase the accuracy of effect size estimates. Previous studies
have shown that similar adjustments for known prognostic fac-
tors increases statistical power in the analysis of time-to-event
outcomes34.
The signal involving rs715212 and rs10963755 was associated
exclusively with disease progression in patients with early onset
and, in a pooled analysis with adjustment for tumour char-
acteristics and study, rs715212 approached a genome-wide level
of signiﬁcance. However, for both SNPs there was no difference in
risk allele frequency between patients with early and late onset.
This suggests that the association may involve an interaction with
another factor that is unique to early-onset patients such as the
expression or somatic mutation proﬁle of the tumour.
Both rs715212 and rs10963755 are located in intron 19 of the
ADAMTSL1 gene which encodes a secreted glycoprotein and is a
member of the ADAMTS (a disintegrin and metalloproteinase
with thrombospondin motif) family (Fig. 4a). Previous studies
have shown that ADAMTSL1 is a component of the extracellular
matrix that may function in cell–cell or cell–matrix interactions
or may regulate other ADAMTS proteases35. Although
ADAMTSL1 is primarily expressed in skeletal muscle, it has been
seen in other tissues including breast and methylation studies
have shown that it is hypermethylated in ER-positive breast
cancer tumours36,37.
We have shown that rs715212 is nominally associated with the
expression of AREG and that the chromatin surrounding
rs715212 is predicted to be functional. These ﬁndings provide
tentative evidence that rs715212 and/or linked variants may
inﬂuence disease progression in early-onset patients by altering
the methylation or functionality of ADAMTSL1 and/or the
expression of AREG either directly or via regulation of other
members of the ADAMTS gene family. However, it is important
to stress that further functional studies are required to verify the
association between rs715212 and AREG expression and deter-
mine the biological mechanism.
Of the two remaining SNPs with moderate association,
rs12302097 is associated with disease progression in all patients
and rs410155 is associated with OS in all patients. For
rs12302097, we have shown that SNPs in weak LD are associated
with the expression of both ﬂanking genes (CHST11 and
TXNRD1) and both of these genes have previously been asso-
ciated with breast cancer38–41. This suggests that CHST11 and or
TXNRD1 may inﬂuence prognosis.
The ﬁnal variant, rs410155, is located between two metal-
lothionein genes, MT3 and MT4. While MT4 has not been
HR: 1.28 (1.14–1.43) 
Ppooled=1.94×10–5
HR: 1.20 (1.04–1.39) HR: 1.28 (1.13–1.46) 
Ppooled=1.65×10–4 Ppooled=0.015
AA (events/N: 303/1135)
CC (events/N: 77/187)
CA (events/N: 318/971)
rs715212
AA (events/N: 1067/4916)
GG (events/N: 12/35)
GA (events/N: 233/874)
rs12302097
GG (events/N: 300/1139)
CC (events/N: 69/198)CG (events/N: 320/949)
rs10963755
TT (events/N: 882/5034)
CC (events/N: 8/43)
CT (events/N: 173/871)
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Fig. 3 Kaplan–Meir survival plots for the four most signiﬁcant SNPs identiﬁed by meta-analyses. Kaplan–Meier plots from univariate analysis of the most
signiﬁcant SNP associated with disease-free survival (DFS) in cases with early onset (a, rs715212 and b, rs10963755), DFS in all cases (c, rs12302097) and
overall survival (OS) in all cases (d, rs410155). For OS, the data from all ﬁve cohorts (ABCFS, HEBCS, POSH stages 1 and 2 and SUCCESS-A) was pooled
whereas for DFS data were pooled across four cohorts because DFS was not recorded in the ABCFS cohort. HR: hazard ratio with 95% conﬁdence interval
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associated with breast cancer, MT3 is overexpressed in breast
cancer cells, which is associated with increased invasiveness and
higher concentrations of matrix metallopeptidase 330,31. These
ﬁndings suggest that elevated expression ofMT3may underlie the
association that we have identiﬁed between overall survival and
genetic variation at rs410155.
The genome-wide signiﬁcant SNPs identiﬁed by previous stu-
dies were both associated with survival in ER-negative
patients32,33. We therefore repeated the stage-1 meta-analysis
using ER-negative patients only (n= 1637) but failed to replicate
the ﬁndings for rs4458204 (Pmeta= 0.771) and rs2059614 (Pmeta
= 0.482) despite a small overlap in the patients tested by these
studies (n= 196 from HEBCS for rs2059614 and n= 315 from
POSH for rs4458204). However, the current study lacks power to
replicate these ﬁndings given the small number of ER-negative
patients and low MAF for rs4458204 (MAF=0.12) and rs2059614
(MAF=0.03).
In a subsequent study which aimed to replicate SNPs with
suggestive signiﬁcance levels using the same patient cohorts, Pirie
et al.10 identiﬁed 12 variants with nominal signiﬁcance (P< 0.05)
including 7 that were associated with ER-positive disease. Eleven
of these SNPs were genotyped and tested by the current study
which replicated the association with rs1800566 in all patients
(Pmeta= 0.01) and rs10477313 in ER-positive patients (Pmeta=
0.013). The nine remaining variants showed no evidence of
association, although ﬁve of these had MAF < 0.1.
The current study has several limitations which must be noted.
First, no variants were identiﬁed at a genome-wide level of sig-
niﬁcance and the most signiﬁcant results were derived from a
multivariable analysis which adjusted for the confounding effect
of tumour characteristics. Second, none of the survival analyses
were adjusted for treatment and the ABCFS cohort could not be
included in the analyses of DFS, early onset and multivariable
models because these variables were unavailable. Third, although
the study is well powered to detect common SNPs we estimate
that it only has 20% power to detect rare SNPs (MAF=0.1)
associated with DFS with HRs of 1.31 for all patients and 1.44 for
those with early onset. Fourth, the associations with gene
expression involve healthy participants and have relatively
modest signiﬁcance levels. Further analysis with larger sample
sizes and adjustment for additional clinicopathological factors
including treatment (chemotherapy and hormone therapy) may
provide more information that could further improve survival
analysis. Further functional studies involving breast cancer
patients and including epigenetic mechanisms should be per-
formed to provide more insights about the three association
signals identiﬁed in the present study.
Our meta-analysis identiﬁed three independent signals asso-
ciated with breast cancer prognosis that are independent of the
classical prognostic factors. Interestingly, the signal located in
ADAMTSL1 was only associated with disease progression in
patients with early onset. This suggests that unique disease
mechanisms may inﬂuence survival in younger women and
provide some biological insight into why younger-onset breast
cancer has a worse prognosis. We have also discussed the possible
impact of these variants on the methylation of ADAMTSL1, its
interaction with other members of the ADAMTS gene family and
their association with the expression of other biologically relevant
Table 3 Univariable and multivariable analysis of pooled data
Covariates at diagnosis Univariable Multivariable
HR (95% CI) Punivariable Events/cases HR (95% CI) Pmultivariable
Model 1 (DFS early onset)
rs715212 1.28 (1.14–1.43) 1.94 × 10−5 698/2293 1.38 (1.23–1.56) 5.37 × 10−8
ER status 0.78 (0.67–0.91) 0.001 702/2295 1.09 (0.90–1.31) 0.377
Grade 1.53 (1.33–1.75) 1.92 × 10−9 684/2260 1.37 (1.17–1.61) 9.05 × 10−5
Tumour size (mm) 1.02 (1.01–1.02) 1.00 × 10−13 667/2258 1.01 (1.01–1.02) 1.01 × 10−13
Nodal status 2.54 (2.16–3.00) 1.00 × 10−13 676/2271 2.37 (1.98–2.83) 1.00 × 10−13
Cohort 0.63 (0.59–0.67) 1.00 × 10−13 705/2315 0.62 (0.58–0.67) 1.00 × 10−13
Model 2 (DFS early onset)
rs10963755 1.21 (1.09–1.36) 0.00065 689/2286 1.27 (1.13–1.43) 4.51 × 10−5
ER status 0.78 (0.67–0.91) 0.00117 702/2295 1.10 (0.92–1.33) 0.301
Grade 1.53 (1.33–1.75) 1.92 × 10−9 684/2260 1.38 (1.18–1.62) 7.33 × 10−5
Tumour size (mm) 1.02 (1.01–1.02) 1.00 × 10−13 667/2258 1.01 (1.01–1.02) 1.00 × 10−13
Nodal status 2.54 (2.16–3.00) 1.00 × 10−13 676/2271 2.31 (1.93–2.77) 1.00 × 10−13
Cohort 0.63 (0.59–0.67) 1.00 × 10−13 705/2315 0.63 (0.58–0.68) 1.00 × 10−13
Model 3 (DFS all cases)
rs12302097 1.28 (1.13–1.46) 1.65 × 10−4 1312/5825 1.26 (1.10–1.44) 0.001
ER status 0.66 (0.59–0.74) 7.11 × 10−13 1298/5756 0.80 (0.70–0.91) 0.001
Grade 1.50 (1.37–1.65) 1.00 × 10−13 1261/5695 1.56 (1.40–1.73) 1.01 × 10−13
Tumour size (mm) 1.02 (1.02–1.02) 1.00 × 10−13 1256/5711 1.02 (1.01–1.02) 1.00 × 10−13
Nodal status 1.98 (1.75–2.24) 1.00 × 10−13 1274/5747 2.10 (1.84–2.41) 1.00 × 10−13
Cohort 0.61 (0.58–0.64) 1.00 × 10−13 1316/5840 0.58 (0.55–0.62) 1.00 × 10−13
Model 4 (OS all cases)
rs410155 1.20 (1.04–1.39) 0.0154 1063/5945 1.28 (1.09–1.51) 0.0023
ER status 0.60 (0.53–0.68) 1.00 × 10−13 1081/5919 0.66 (0.57–0.77) 5.92 × 10−8
Grade 1.72 (1.54–1.91) 1.00 × 10−13 990/5692 1.65 (1.46–1.87) 1.06 × 10−13
Tumour size (mm) 1.02 (1.02–1.02) 1.00 × 10−13 981/5708 1.02 (1.02–1.02) 1.00 × 10−13
Nodal status 2.12 (1.85–2.44) 1.00 × 10−13 998/5744 2.22 (1.90–2.59) 1.00 × 10−13
Cohort 0.79 (0.76–0.83) 1.00 × 10−13 1101/6039 0.67 (0.63–0.71) 1.00 × 10−13
Univariable and multivariable analyses were performed with pooled data from ABCFS, HEBCS, POSH (stages 1 and 2) and SUCCESS-A for overall survival (OS). The ABCFS cohort was excluded from the
analysis of disease-free survival (DFS). For univariate analyses, the number of events and cases is slightly different for each covariate due to variation in the number of cases with missing data. For
multivariable analyses, the following number of events and cases were used: model 1: 642/2172, model 2: 634/2166, model 3: 1201/5538, model 4: 911/5482. In each model the hazard ratios (HRs) and
95% conﬁdence interval (CI) were adjusted for oestrogen receptor status (ER), grade, maximum tumour size, nodal status, SNP and cohort. Punivariable, P-values from univariable Cox regression;
Pmultivariable, P-values from multivariable Cox regression.
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genes such as AREG in the context of breast cancer prognosis.
The SNPs identiﬁed in this study have the potential to improve
the accuracy of prognostic estimates and stratiﬁcation of patients
into treatment groups. Moreover, the gene implicated by these
SNPs may warrant further investigation as novel therapeutic
targets and some are already under investigation for this purpose.
Methods
Patient cohorts for discovery and replication stages. At stage-1, breast cancer
samples were selected from four cohorts: (1) ABCFS (http://epi.unimelb.edu.au/
research/cancer/breast/)42, (2) HEBCS43, (3) POSH from the United Kingdom44
and (4) a prospective randomized phase III clinical trial comparing FEC-Doc
Chemotherapy vs. FEC DocG chemotherapy (SUCCESS-A) from Germany45. Prior
to QC, these data sets consisted of: 214 incident cases in ABCFS diagnosed between
1992 and 1995 with a ﬁrst primary invasive breast cancer before the age of 40 years
and living in Melbourne or Sydney; 832 breast cancer patients in HEBCS aged
22–96 years and treated in the Helsinki region between 1997 and 2004; 574 patients
from the POSH study aged ≤ 40 years at diagnosis of invasive breast cancer
between 2000 and 2007; and 3277 patients from the SUCCESS-A trial diagnosed
with primary epithelial invasive carcinoma and recruited between 2005 and 2007
(Supplementary Table 1). All patients gave informed consent and the studies were
approved by the relevant ethics committees42–45. Histopathological and survival
data were collected for all patients. In HEBCS, 590 patients were unselected and
242 were familial43. In the POSH cohort, 274 patients were genotyped as part of a
larger study on TNBC in which there is little or no tumour expression for ER, PR
and human epidermal growth factor receptor 2 (HER2)46. To increase power, the
remaining samples from the POSH cohort were enriched for survival extremes
corresponding to patients with early distant metastasis or death (n= 193, median
OS=2.8 years) and patients with long-term event free survival (n= 96, median
OS=8.7 years).
A further 1303 patients from the POSH cohort44 who were unselected for any
survival differences and were independent of the stage-1 data set were used for
replication analysis at stage-2 (Supplementary Table 1). These patients were aged
≤ 40 years at diagnosis of invasive breast cancer and had self-reported ethnicities of
White/Caucasian (n= 1285), eastern European (n= 3), Greek (n= 2), South
African (n = 2) and Jewish (n= 11).
To assess the similarity of clinicopathologic features between all cohorts with
data (n= 3 to 5), Pearson’s χ2 test was used for categorical traits and
Kruskal–Wallis rank sum tests were used for continuous traits (Table 1).
Genotyping and QC at stage-1. At stage-1, samples were genotyped using the
Illumina 610k array for ABCFS, Illumina 550K array for HEBCS47, Illumina 660-
Quad array for POSH by The Mayo Clinic (Rochester, MN, USA) and Genome
Institute of Singapore (GIS)48 and the HumanOmniExpress-FFPE BeadChip for
SUCCESS-A. Standard QC measures were applied to the genotypic data from
stage-1, which removed SNPs with MAFs of < 5%, SNPs and individuals with
> 10% missing genotypes and SNPs with signiﬁcant deviations from
Hardy–Weinberg equilibrium (P-value ≤ 1 × 10−10). Strand issues, where the allele
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Fig. 4 Regional plots of association with survival (OS or DFS) at stage-1 meta-analysis, recombination rate and gene context for the most signiﬁcant SNPs.
Results from the stage-1 meta-analyses in a region surrounding the most signiﬁcant SNP associated with DFS in patients with early onset (a, rs715212 and
rs10963755), DFS in all patients (b, rs12302097) and OS in all patients (c, rs410155). In each plot, a purple diamond identiﬁes the index SNP and the colour
of other SNPs represent their linkage disequilibrium (r2) with the index SNP from light blue (r2≤ 0.4) to red (r2≥ 0.8). The middle panel displays the
15 state chromatin segmentation track (ChromHMM) in breast variant human mammary epithelial cells (vHMECs, E028), mammary epithelial primary
cells (HMECs, E119) and breast myoepithelial primary cells (E027) using data from the HapMap ENCODE Project. The lower panels show genes and their
direction of transcription (arrows). Physical positions are relative to build 37 (hg19) of the human genome
NATURE COMMUNICATIONS | DOI: 10.1038/s41467-017-01775-y ARTICLE
NATURE COMMUNICATIONS |8:  1632 |DOI: 10.1038/s41467-017-01775-y |www.nature.com/naturecommunications 9
coding differs between cohorts, were resolved by combining the cohorts and ﬂip-
ping strands for SNPs with more than two alleles and by ensuring that the MAFs
were similar between cohorts particularly for A/T and G/C SNPs where strand
issues cannot be detected by allelic excess. The reported gender of the individuals
was veriﬁed against that predicted from their genotypic data. All duplicate samples,
individuals with incomplete phenotypic data for survival analyses and samples that
were cryptically related (pairwise-identity by state > 86%) were excluded from the
stage-1 cohorts. Samples that were inferred to have non-European ancestry by
multidimensional scaling analysis against reference populations from HapMap
were excluded so that the remaining samples in each cohort formed a single cluster
which overlapped with the Caucasian reference (CEU, Supplementary Fig. 1).
Across the four stage-1 cohorts, a total of 143,380 SNPs and 158 patients were
removed during these QC steps leaving 4739 patients and observed genotypes at
813,964 SNPs for analysis. The number of SNPs and patients removed and
remaining in each cohort is shown in Supplementary Table 1. All QC procedures
were carried out using PLINK49.
Imputation of the stage-1 data and further QC. To aid meta-analysis and to
increase the resolution of the stage-1 data, additional SNPs were imputed using
MACH 1.0 (http://www.sph.umich.edu/csg/abecasis/MACH/index.html). The
reference data for imputation were SNP genotypes from HapMap phase 2 and
phased haplotypes from the CEPH population (Utah residents with ancestry from
northern and western Europe, CEU). The imputed genotypes were quality con-
trolled by excluding SNPs with: a posterior probability < 0.9, MAF <5%, >10%
missing genotypes or signiﬁcant deviations from Hardy–Weinberg equilibrium (P-
value≤ 1 × 10−10). Following these QC steps, 5,848,861 imputed SNPs across the
four stage-1 cohorts remained for analysis (Supplementary Table 1).
Power calculations. The power to detect SNPs associated with OS and DFS in all
cases and patients with early-onset breast cancer in the combined stage-1 cohorts
was estimated using the survSNP program in R50 with an additive genetic risk
model and type 1 error rate (α) of 5 × 10−8 (Supplementary Fig. 2). A range of
modest genotype HRs (1.1–2.0) and risk allele frequencies (0.05–0.3) were used
along with the documented values for sample size and event rate after QC (Sup-
plementary Table 1).
Cox regression. To identify SNPs inﬂuencing prognosis we used the formetascore
command in GenABEL51 to perform Cox regression analyses of OS and DFS, with
correction for ER status which is the only variable that is recorded in all four
cohorts, has the most complete data and is associated with survival52. SNPs were
coded according to the number of rare alleles (0–2). For OS, follow-up times were
deﬁned as the duration between breast cancer diagnosis and death from any cause
or last follow-up if alive. For DFS, the follow-up times were deﬁned as the time
between diagnosis and disease progression in the form of local recurrence, distant
metastasis or death from any cause, whichever occurred ﬁrst, or last follow-up if
alive. Patients who had not experienced an event at the time of analysis were
censored at their date of last follow-up.
To identify variants associated with early-onset breast cancer, the OS and DFS
analyses were repeated in a subset of 2315 patients who were aged ≤ 40 years at
diagnosis from HEBCS (n= 119), POSH stage-1 (n = 556), POSH stage-2 (n=
1303) and SUCCESS-A (n= 337). For the early-onset analysis, the POSH cohort
was particularly important because all of the POSH patients were aged ≤ 40 years
at diagnosis. The ABCFS data set did not contain data on age of onset, local
recurrence or distant metastasis and therefore could not be used for the analysis of
DFS or early onset. For SNPs associated with early onset, the relationship between
prognosis and onset age was further explored by: (1) repeating the OS and DFS
survival analyses in a subset of patients from HEBCS (n = 679) and SUCCESS-A
(n= 2846) that were aged > 40 years at diagnosis and (2) testing for allelic
association with OS and DFS events in patients with early (aged ≤40 years at
diagnosis) and late onset (aged > 40 years at diagnosis) using Pearson's χ2 test.
The mean difference in time between age at diagnosis and age at registration
was 0.78 years (s.d.=1.16 years) over all cohorts.
Visualization of stage-1 results. To verify the robustness of our QC measures and
to examine the possibility of confounding factors such as population stratiﬁcation,
we used the qqnorm and qqplot procedures in R53 to generate QQ plots of the
observed and expected P-values under the null distribution in the stage-1 data
(Supplementary Figs. 3–5).
To visualise the stage-1 results and SNPs selected for follow-up, the qqman
package in R54 was used to generate a Manhattan plot and highlight the most
signiﬁcant SNPs associated with OS and DFS (Fig. 1). For SNPs with signiﬁcant
replication, Locus Zoom55 was used to generate regional plots of the stage-1 data to
show the pattern of association surrounding the index SNP with respect to LD with
neighbouring SNPs, underlying recombination rate and gene context (Fig. 4).
Meta-analysis. To select SNPs for follow-up at stage-2, we used PLINK49 to
perform a ﬁxed effects inverse variance-weighted meta-analysis of the stage-1
results for OS and DFS in all cases and the subset of patients with early onset. A
ﬁxed effects meta-analysis was used under the assumption that SNPs have one true
effect size and that any differences between studies were most likely to be due to
sampling variation. To estimate heterogeneity in effect size between studies we used
the χ2-based Cochran Q-statistic and I2 which gives the percentage of variation
across studies that is due to heterogeneity rather than chance56. The same meth-
odology was used to determine the ﬁnal signiﬁcance and effect size of SNPs by
meta-analysis of the Cox regression results from stages 1 and 2. To visualise the
meta-analysis, we produced a forest plot using Stata version 12 (Fig. 2)57. Following
meta-analysis of stages 1 and 2, data from all cohorts were pooled and KM plots
were generated for the most signiﬁcant SNPs using Stata version 1257.
False positive report probability. To assess the reliability of the associations from
meta-analysis of stages 1 and 2 we calculated the FPRP which describes the
probability of no true association between a genetic variant and disease, given a
statistically signiﬁcant ﬁnding58. The FPRP was calculated using a low prior
probability of 0.0001, which is expected for a random SNP, to detect a hazard ratio
of 1.3. A threshold of FPRP ≤ 0.2 was used to identify noteworthy associations.
Selection, genotyping and QC of SNPs at stage-2. Completely unbiased
methods of SNP selection have no means of excluding false positives which are
likely to be among the most signiﬁcant signals. They will also neglect moderately
signiﬁcant SNPs in favour of the most signiﬁcant SNPs despite potentially over-
whelming support from correlated SNPs and proximity to biologically relevant
genes. To select the most promising SNPs for follow-up, we therefore used a
clumping procedure in PLINK49 to generate a shortlist of index SNPs with support
from correlated SNPs (SNPs r2≥ 0.5, within 500 kb). Priority, but not exclusivity,
was then given to index SNPs that were close to a relevant gene according to
annotation from GeneAlacart (https://genealacart.genecards.org/). Two shortlists
of index SNPs were made which used either a stringent (index SNP Pmeta≤ 0.001
and correlated SNP Pmeta≤ 0.01) or moderate set of P-value thresholds (index SNP
Pmeta≤ 0.01 and correlated SNP Pmeta≤ 0.1). SNPs were selected from the stringent
shortlist ﬁrst (n= 50) and then from the moderate shortlist (n= 37). Since priority
but not exclusivity was given to SNPs close to relevant genes, 20 SNPs were selected
on a completely unbiased basis and 67 were selected from the unbiased shortlist
because they were close to a relevant gene (Supplementary Data 1).
To select additional SNPs, we performed a literature search, which identiﬁed 73
variants that have previously been associated with breast cancer survival (OS, DFS
or breast cancer-speciﬁc survival) in independent cohorts. These published SNPs
were cross-referenced with our stage-1 meta-analysis and 8 additional SNPs were
selected on the basis of their published association with onset age and/or because
the gene implicated had potential applications for diagnosis, risk prediction or
therapeutic intervention.
The 95 SNPs selected for replication were genotyped by LGC Genomics
(Hoddeson, UK) in 1303 patients from the POSH cohort. The genotypes were
quality controlled by excluding SNPs with >10% duplicate error rate, >10%
missing genotypes or signiﬁcant deviations from Hardy–Weinberg equilibrium (P-
value≤ 1 × 10−10).
Multivariable Cox regression. We used multivariable Cox regression in pooled
data from stages 1 and 2 to determine whether SNPs with the most signiﬁcant
impacts on survival were independent of the known prognostic factors that were
available across all studies. Data on ER status (negative=0, positive=1) tumour
grade (1 to 3), maximum tumour diameter (mean 25.7, range 0 to 220 mm) and
axillary nodal status (not affected=0, affected=1) were available for 93% of the
cases that passed QC (n= 5622/6042). These prognostic factors along with the
cohort used were treated as covariates and were entered into the proportional
hazards model in order of signiﬁcance. All survival analyses were carried out using
Stata version 12 and the P-values reported were two-sided at 5% signiﬁcance.
Functional annotation of signiﬁcant SNPs. To explore the functional relevance of
the regions associated with survival, we used HaploReg v4.121, RegulomeDB22 and
SeattleSeq23 to interrogate ENCODE data59 and annotate the risk SNPs and their
linked SNPs (r2≥ 0.2) with respect to: histone modiﬁcations, DNAseI hypersen-
sitivity, proteins bound, disruption of regulatory motifs, conservation metrics from
genomic evolutionary rate proﬁling (GERP)60 and combined annotation-
dependent depletion scores (CADD)61, and functionality scores from Reg-
ulomeDB. The scores from RegulomeDB were generated using data from Gene
Expression Omnibus (GEO), ENCODE and published literature. Variants with a
RegulomeDB score of 3 are likely to affect binding while variants scoring 4–6 have
minimal evidence for functional activity.
Additionally, candidate regions were annotated with 15 state chromatin
segmentation in breast vHMECs (E028), mammary epithelial primary cells
(HMEC, E119) and breast myoepithelial primary cells (E027). These chromatin
states categorize noncoding DNA into functional regulatory elements such as
enhancers and quiescent regions that are respectively enriched and depleted for
phenotype-associated SNPs62. The chromatin states were generated by
computational integration of binarized chromatin immunoprecipitation
sequencing data using a multivariable Hhidden Markov model that explicitly
models the combinatorial patterns of observed modiﬁcations63.
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To gain further functional insight, eQTL analysis was performed for all SNPs in
LD (r2≥ 0.2) with the index SNPs using the GTEx portal (V6, dbGaP Accession
phs000424.v6.p1)24 to query RNAseq data from breast mammary tissue in
183 samples with genotype data.
Data availability. All relevant summary statistics from the ABCFS, HEBCS and
POSH cohorts are available from the authors for collaborative research upon
request to the corresponding author. The SUCCESS-A data are available via
authorized access from dbGaP (Study Accession: phs000547.v1.p1).
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